- Home
- EVCM vs DNLI Comparison
EVCM vs DNLI Comparison
Compare EVCM & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVCM
- DNLI
- Stock Information
- Founded
- EVCM 2006
- DNLI 2013
- Country
- EVCM United States
- DNLI United States
- Employees
- EVCM N/A
- DNLI N/A
- Industry
- EVCM EDP Services
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVCM Technology
- DNLI Health Care
- Exchange
- EVCM Nasdaq
- DNLI Nasdaq
- Market Cap
- EVCM 1.8B
- DNLI 2.1B
- IPO Year
- EVCM 2021
- DNLI 2017
- Fundamental
- Price
- EVCM $9.55
- DNLI $13.89
- Analyst Decision
- EVCM Buy
- DNLI Strong Buy
- Analyst Count
- EVCM 12
- DNLI 15
- Target Price
- EVCM $11.67
- DNLI $33.85
- AVG Volume (30 Days)
- EVCM 206.3K
- DNLI 1.6M
- Earning Date
- EVCM 08-05-2025
- DNLI 07-31-2025
- Dividend Yield
- EVCM N/A
- DNLI N/A
- EPS Growth
- EVCM N/A
- DNLI N/A
- EPS
- EVCM N/A
- DNLI N/A
- Revenue
- EVCM $703,186,000.00
- DNLI N/A
- Revenue This Year
- EVCM N/A
- DNLI N/A
- Revenue Next Year
- EVCM $6.31
- DNLI $335.74
- P/E Ratio
- EVCM N/A
- DNLI N/A
- Revenue Growth
- EVCM 7.84
- DNLI N/A
- 52 Week Low
- EVCM $8.10
- DNLI $10.57
- 52 Week High
- EVCM $12.35
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- EVCM 39.61
- DNLI 45.02
- Support Level
- EVCM $9.44
- DNLI $14.19
- Resistance Level
- EVCM $9.82
- DNLI $14.88
- Average True Range (ATR)
- EVCM 0.29
- DNLI 0.77
- MACD
- EVCM -0.06
- DNLI -0.03
- Stochastic Oscillator
- EVCM 14.01
- DNLI 34.55
About EVCM EverCommerce Inc.
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. With a platform serving approximately 708,000 customers across three core verticals, including numerous micro-verticals, their solutions address diverse needs within these sectors. Revenue is primarily generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty. The majority of customers contribute modest revenue, with a small percentage contributing higher amounts.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.